Stifel’s Biopharmaceutical Outlook for 2025 and review of 2024 reveals the challenges for the biotech market as we start the year. DealForma data highlights the trends in licensing, M&A, and investment. Definitely an important weekly report from Tim Opler and team. Read the article here

Deals and funding for cell and gene therapies have declined from recent highs, but emerging technologies and new applications may drive a rebound, supported by data from the DealForma database. Read the article here

Raveena Bhambra from Nature reports that nucleic-acid-based drugs are driving broader investments, dealmaking, and market expansion beyond rare diseases, with DealForma providing the deal history. Read the article here

Bruce Booth presented the Atlas Venture 2024 Year in Review in the most valuable hour reviewing licensing, venture, drug development, M&A and more. Honored to be a data source with DealForma in the charts. Watch this presentation.

Bloomberg, citing DealForma data, reports Western pharma firms spent $3.15 billion on Chinese drug molecules in 2024, a rare collaborative bright spot facing heightened scrutiny under Trump and the Biosecure Act. Check out Bloomberg’s report.

Stifel’s weekly biopharma update, with data partly compiled by DealForma, highlights industry uncertainty from U.S. Election volatility, steady IPO activity, subdued M&A, and promising obesity drug developments, with new research linking sugar addiction to obesity management. Check out Stifel’s report.

Stifel’s weekly biopharma update covers biotech’s strong 2024 performance, Starboard Value’s activist move on Pfizer, and China’s shifting biotech sector, with data partly compiled by DealForma, plus insights on M&A trends and macroeconomic factors. Check out Stifel’s report.

In Q3 2024, despite mixed indicators for biotech business activity, DealForma’s numbers show that the industry is on track to surpass 2023’s deal totals, though a strong finish in Q4 will be crucial for exceeding last year’s licensing upfronts. Check out Endpoints report.

Stifel’s weekly biopharma update, using data from DealForma, provides an update on the biopharma market for the week of October 7, 2024, discussing strong U.S. jobs data, geopolitical tensions, market volatility, a China stimulus, trends in biotech stocks, capital raising activities, and M&A developments ahead of the U.S. presidential election. Check out Stifel’s report.

BioPharma Dive’s report, leveraging DealForma’s data, uncovers a steep decline in investment for cell and gene therapy developers, attributed to manufacturing and drug delivery challenges, as investors increasingly favor biotechnology companies with more defined development paths. Check out Biopharma Dive’s report.

Stifel’s report, utilizing DealForma’s data, outlines the recent market turbulence, focusing on the sharp declines in tech and biotech stocks due to changes in Japanese interest rates and the resulting impact on investors, while also addressing the potential effects of upcoming political events on the biotech sector. Explore Stifel’s research.

The WSJ article, using data from DealForma, discusses how major pharmaceutical companies have scaled down their acquisition strategies in 2024, focusing on smaller targets priced at $5 billion or less, primarily due to tighter regulatory scrutiny and a smaller pool of large-scale acquisition targets. Check out WSJ’s article.